Placenta-on-a-chip study addresses potential effects of pharmaceutical agents on fetus
Concerns about the impact of pharmaceutical agents on fetal development have prompted researchers at Iowa State University to undertake a key study using a placenta-on-a-chip model. The study, focused on the transport of naltrexone (NTX) and its primary metabolite 6β-naltrexol, sheds light on their potential effects on the developing neural system of fetuses and their premature brains.
The placenta-on-a-chip model was fabricated and meticulously tested to simulate the transport of NTX/6β-naltrexol from the maternal channel to the fetal channel. From the fetal channel, the transported NTX/6β-naltrexol was collected and directed toward cultured N27 neural cells. The neural cells were then evaluated for gene expression and cell viability following exposure to the pharmaceutical agents.
The study revealed intriguing findings, notably the significantly higher fold changes in interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) expression in neural cells exposed to NTX/6β-naltrexol. Conversely, the fold change in interleukin-1 beta (IL-1β) expression was lower, while the sphingosine kinase 1 (sphk1) expression remained constant. Moreover, cell viability was significantly lower when exposed to NTX/6β-naltrexol.
These results hold particular significance since previous reports have linked elevated IL-6 and IL-1β expression levels to increased plasma levels in fetal brains and acute inflammatory insults in developing brains. Similarly, the possibility of TNF-α reducing embryonic brain development has been reported. On the other hand, sphk1 enzyme is associated with increasing cell survival and proliferation, contributing to standard physiological functions in developing brain cells.
During the study, the mean fetal concentrations of NTX and 6β-naltrexol over an 8-hour interval were recorded. The findings provide critical insights into how NTX/6β-naltrexol affects embryonic brain cells, further supporting the need for ongoing research in this area.
By utilizing advanced liquid chromatography/mass spectrometry (LC-MS), the study effectively analyzed the transport of clinically relevant concentrations of NTX and 6β-naltrexol.
“This proof-of-concept marks an important step forward in understanding the impact of pharmaceutical agents on the developing neural system and premature brains of fetuses.” said Nicole Hashemi, the principal investigator on the project. “As we delve deeper into these mechanisms, we hope to contribute to the development of safer medications for pregnant women and their unborn children.”
The placenta-on-a-chip microsystems have potential in transforming our understanding of how pharmaceutical agents affect fetal development. This technology can provide insights into the complex processes that occur during pregnancy, ensuring safer and more informed medical practices.
While this study has made major strides, the researchers emphasize the need for further studies to validate and expand upon these findings. Continued research in this field is vital to ensure the well-being of both mothers and their unborn children.
The study is published in the journal Innovation and Emerging Technologies.
More information: Rajeendra L. Pemathilaka et al, Placenta-on-a-chip: Response of neural cells to pharmaceutical agents transported across the placental barrier, Innovation and Emerging Technologies (2023). DOI: 10.1142/S2737599423400042
New research points to dad’s drinking as a significant factor in fetal alcohol syndrome
Men drink more, are more likely to binge drink and are almost four times more likely to develop alcohol use disorder than women, according to the Centers for Disease Control and Prevention.
Yet when it comes to diagnosing babies born with birth defects associated with alcohol consumption, such as fetal alcohol syndrome, historically only the mother’s drinking habits are taken into consideration.
Research clearly shows that sperm carry a vast amount of epigenetic information—meaning heritable shifts in the way genes are expressed that don’t result from changes in the DNA sequence—that strongly influences fetal development and child health. Yet most doctors and other health care providers do not take into account the influence of paternal health and lifestyle choices on child development.
I am a developmental physiologist, and my research explores the ways that male drinking affects fetal development.
While most of the attention is given to the mom’s drinking while pregnant, my team and I focus on male drinking in the weeks and months before conception. Our studies are the first to demonstrate that male drinking before pregnancy is a plausible yet completely unexamined factor in the development of alcohol-related craniofacial abnormalities and growth deficiencies.
The intense focus on mom
In 1981, the U.S. surgeon general issued a public health warning that alcohol use by women during pregnancy was the cause of physical and mental birth defects in children.
